Get the Stockscreener App
79.74
3.31%
-2.73
Vaxcyte Inc stock is traded at $79.74, with a volume of 1.22M.
It is down -3.31% in the last 24 hours and down -9.56% over the past month.
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG.
See More
Previous Close:
$82.47
Open:
$83.77
24h Volume:
1.22M
Relative Volume:
1.06
Market Cap:
$9.94B
Revenue:
-
Net Income/Loss:
$-507.65M
P/E Ratio:
-17.33
EPS:
-4.6
Net Cash Flow:
$-616.24M
1W Performance:
-5.07%
1M Performance:
-9.56%
6M Performance:
-0.10%
1Y Performance:
+10.35%
1-Day Range:
$79.51
$84.01
1-Week Range:
$79.51
$85.22
52-Week Range:
$58.10
$121.06
Vaxcyte Inc Stock (PCVX) Company Profile
Name
Vaxcyte Inc
Sector
Industry
Phone
650-837-0111
Address
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Compare PCVX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
79.74 | 9.94B | 0 | -507.65M | -616.24M | -4.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Initiated | Goldman | Buy |
| Dec-07-23 | Initiated | Mizuho | Buy |
| Apr-18-23 | Initiated | TD Cowen | Outperform |
| Jan-03-23 | Reiterated | Needham | Buy |
| Dec-15-22 | Initiated | Guggenheim | Buy |
| Nov-17-22 | Initiated | BTIG Research | Buy |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Jun-24-21 | Resumed | Jefferies | Buy |
| Jul-07-20 | Initiated | BofA Securities | Buy |
| Jul-07-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-07-20 | Initiated | Needham | Buy |
View All
Vaxcyte Inc Stock (PCVX) Latest News
Vaxcyte, Inc. (NASDAQ:PCVX) CFO Sells $670,800.00 in Stock - MarketBeat
Vaxcyte president and CFO sells $670,822 in stock By Investing.com - Investing.com South Africa
State of New Jersey Common Pension Fund D Purchases 5,427 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
Vaxcyte president and CFO sells $670,822 in stock - Investing.com India
Vaxcyte Executive Sells Shares Under Trading Plan - TradingView
Vaxcyte (PCVX) to Release Quarterly Earnings on Tuesday - MarketBeat
TimesSquare Capital Management LLC Boosts Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
Vaxcyte, Inc. (NASDAQ:PCVX) Stock Holdings Lowered by Banque Pictet & Cie SA - MarketBeat
Vaxcyte, Inc. (NASDAQ:PCVX) Shares Purchased by Allspring Global Investments Holdings LLC - MarketBeat
Vaxcyte SVP Mikhail Eydelman sells $450k in stock - MSN
Vaxcyte's (PCVX) "Buy" Rating Reiterated at Needham & Company LLC - MarketBeat
WCM Investment Management LLC Sells 68,753 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 - GlobeNewswire
Vaxcyte, Inc. to Announce Q4 and Full Year 2024 Financial Results on February 25, 2025 - Nasdaq
Vaxcyte Sets Stage for Major Q4 Revelations: Vaccine Innovation Updates & Financial Deep-Dive Coming - StockTitan
abrdn plc Buys 141,994 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
Vaxcyte COO Jim Wassil sells $689,790 in stock - MSN
Calamos Advisors LLC Lowers Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
Vaxcyte, Inc. (NASDAQ:PCVX) COO Sells $689,760.00 in Stock - MarketBeat
Vaxcyte advances to final stage in infant vaccine study - MSN
Why Vaxcyte, Inc. (PCVX) Is Among the Best Healthcare Stocks To Buy According to Analysts - Yahoo Finance
Jennison Associates LLC Buys 9,121 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
12 Best Healthcare Stocks to Buy According to Analysts - Insider Monkey
Vaxcyte SVP Mikhail Eydelman sells $450k in stock By Investing.com - Investing.com Nigeria
Vaxcyte’s Promising Pipeline and Growth Potential Justifies Buy Rating - TipRanks
Vaxcyte advances to final stage in infant vaccine study By Investing.com - Investing.com Australia
Vaxcyte advances second stage of Phase 2 study evaluating VAX-31 - Yahoo Finance
Vaxcyte enters final stage of Phase II pneumococcal vaccine trial in infants - Clinical Trials Arena
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study - GlobeNewswire
Vaxcyte Advances Phase 2 Study on Infant Pneumococcal Disease Prevention to Final Stage - Marketscreener.com
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants - The Manila Times
Vaxcyte Inc Stock (PCVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vaxcyte Inc Stock (PCVX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| GUGGENHIME ANDREW | PRESIDENT AND CFO |
Feb 18 '25 |
Sale |
83.85 |
8,000 |
670,823 |
109,491 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):